Status:

UNKNOWN

Effect of Alendronate 70mg Formulation on Bone Turnover Markers and Patient Reported Outcomes

Lead Sponsor:

Labatec Pharma SA

Conditions:

Osteoporosis, Postmenopausal

Eligibility:

FEMALE

55-90 years

Brief Summary

Compare the data obtained with two formulations of alendronate 70 mg (tablets vs effervescent tablet for buffered solution) on the change in bone turnover markers, on gastric tolerance and on treatmen...

Eligibility Criteria

Inclusion

  • Post-menopausal women (at least 5 years after natural / surgical menopause).
  • Patients on treatment with alendronate 70mg tablets or alendronate 70mg effervescent tablets for 6-8 months and who will be continued to be treated for a minimum of 12 months.
  • Available BTMs (s-CTX), biochemistry (calcium, phosphate, 25-OH vit D, PTH, creatinine) and DXA (lumbar spine, total hip and femoral neck) at the initiation of the treatment.
  • Ability to sign an informed patient consent

Exclusion

  • Patients who had received a prior osteoporosis treatment with anti-resorptive drugs (bisphosphonate or denosumab) or teriparatide before starting alendronate 70 mg.
  • Any secondary cause of osteoporosis including current treatment with glucocorticoids or aromatase inhibitors, inflammatory disorders, malabsorption
  • Metabolic or cancer bone disease
  • Contra-indications to bisphosphonates according to product labelling
  • Known or suspected allergy to study product(s) or related products
  • Inability to sign an informed consent
  • Previous participation in this study

Key Trial Info

Start Date :

February 25 2018

Trial Type :

OBSERVATIONAL

Allocation :

ESTIMATED

End Date :

December 1 2022

Estimated Enrollment :

80 Patients enrolled

Trial Details

Trial ID

NCT03435094

Start Date

February 25 2018

End Date

December 1 2022

Last Update

December 3 2020

Active Locations (2)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (2 locations)

1

Endokrinologische Praxis & Labor

Basel, Canton of Basel-City, Switzerland, 4055

2

Hôpital Universitaire de Genève, Service des maladies osseuses

Geneva, Canton of Geneva, Switzerland, 1211